nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT1A9—Sorafenib—kidney cancer	0.166	0.312	CbGbCtD
Tapentadol—CYP2D6—Temsirolimus—kidney cancer	0.0834	0.156	CbGbCtD
Tapentadol—CYP2C9—Capecitabine—kidney cancer	0.05	0.0937	CbGbCtD
Tapentadol—CYP2D6—Pazopanib—kidney cancer	0.0438	0.0822	CbGbCtD
Tapentadol—CYP2C19—Sorafenib—kidney cancer	0.0334	0.0627	CbGbCtD
Tapentadol—CYP2C9—Paclitaxel—kidney cancer	0.0313	0.0587	CbGbCtD
Tapentadol—CYP2D6—Erlotinib—kidney cancer	0.0313	0.0586	CbGbCtD
Tapentadol—CYP2C9—Sorafenib—kidney cancer	0.0278	0.0521	CbGbCtD
Tapentadol—CYP2D6—Sorafenib—kidney cancer	0.0254	0.0477	CbGbCtD
Tapentadol—CYP2D6—Vinblastine—kidney cancer	0.0251	0.0471	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—kidney cancer	0.0154	0.0289	CbGbCtD
Tapentadol—Edrophonium—ACHE—kidney cancer	0.0044	0.326	CrCbGaD
Tapentadol—Rivastigmine—ACHE—kidney cancer	0.00409	0.303	CrCbGaD
Tapentadol—CYP2C19—urine—kidney cancer	0.00285	0.16	CbGeAlD
Tapentadol—Edrophonium—BCHE—kidney cancer	0.00259	0.192	CrCbGaD
Tapentadol—Rivastigmine—BCHE—kidney cancer	0.00241	0.178	CrCbGaD
Tapentadol—CYP2C9—urine—kidney cancer	0.00221	0.124	CbGeAlD
Tapentadol—UGT1A9—renal system—kidney cancer	0.00188	0.106	CbGeAlD
Tapentadol—UGT1A9—kidney—kidney cancer	0.00181	0.102	CbGeAlD
Tapentadol—CYP2D6—urine—kidney cancer	0.00166	0.0933	CbGeAlD
Tapentadol—UGT2B7—renal system—kidney cancer	0.00151	0.0852	CbGeAlD
Tapentadol—OPRD1—renal system—kidney cancer	0.00148	0.0835	CbGeAlD
Tapentadol—UGT2B7—kidney—kidney cancer	0.00146	0.0823	CbGeAlD
Tapentadol—OPRD1—kidney—kidney cancer	0.00143	0.0807	CbGeAlD
Tapentadol—SLC6A2—gonad—kidney cancer	0.000664	0.0374	CbGeAlD
Tapentadol—CYP2D6—renal system—kidney cancer	0.000406	0.0228	CbGeAlD
Tapentadol—CYP2D6—kidney—kidney cancer	0.000392	0.0221	CbGeAlD
Tapentadol—Hyperhidrosis—Gemcitabine—kidney cancer	0.00034	0.000942	CcSEcCtD
Tapentadol—Hot flush—Doxorubicin—kidney cancer	0.000339	0.000939	CcSEcCtD
Tapentadol—Hypoaesthesia—Capecitabine—kidney cancer	0.000339	0.000938	CcSEcCtD
Tapentadol—Tremor—Paclitaxel—kidney cancer	0.000339	0.000937	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000338	0.000936	CcSEcCtD
Tapentadol—Urinary tract disorder—Capecitabine—kidney cancer	0.000336	0.000931	CcSEcCtD
Tapentadol—Menopausal symptoms—Doxorubicin—kidney cancer	0.000336	0.000931	CcSEcCtD
Tapentadol—Hypersensitivity—Sorafenib—kidney cancer	0.000336	0.00093	CcSEcCtD
Tapentadol—Insomnia—Vincristine—kidney cancer	0.000336	0.000929	CcSEcCtD
Tapentadol—Vomiting—Vinblastine—kidney cancer	0.000335	0.000928	CcSEcCtD
Tapentadol—Dizziness—Erlotinib—kidney cancer	0.000335	0.000928	CcSEcCtD
Tapentadol—Connective tissue disorder—Capecitabine—kidney cancer	0.000335	0.000926	CcSEcCtD
Tapentadol—Vomiting—Everolimus—kidney cancer	0.000334	0.000924	CcSEcCtD
Tapentadol—Urethral disorder—Capecitabine—kidney cancer	0.000334	0.000924	CcSEcCtD
Tapentadol—Paraesthesia—Vincristine—kidney cancer	0.000333	0.000922	CcSEcCtD
Tapentadol—Agitation—Paclitaxel—kidney cancer	0.000332	0.000919	CcSEcCtD
Tapentadol—Rash—Everolimus—kidney cancer	0.000331	0.000917	CcSEcCtD
Tapentadol—Dermatitis—Everolimus—kidney cancer	0.000331	0.000916	CcSEcCtD
Tapentadol—Headache—Vinblastine—kidney cancer	0.00033	0.000914	CcSEcCtD
Tapentadol—Angioedema—Paclitaxel—kidney cancer	0.00033	0.000913	CcSEcCtD
Tapentadol—Headache—Everolimus—kidney cancer	0.000329	0.000911	CcSEcCtD
Tapentadol—Hypotension—Gemcitabine—kidney cancer	0.000329	0.00091	CcSEcCtD
Tapentadol—Visual impairment—Capecitabine—kidney cancer	0.000328	0.000908	CcSEcCtD
Tapentadol—Asthenia—Sorafenib—kidney cancer	0.000327	0.000905	CcSEcCtD
Tapentadol—Vertigo—Paclitaxel—kidney cancer	0.000325	0.000898	CcSEcCtD
Tapentadol—Syncope—Paclitaxel—kidney cancer	0.000324	0.000896	CcSEcCtD
Tapentadol—Lethargy—Doxorubicin—kidney cancer	0.000324	0.000896	CcSEcCtD
Tapentadol—Hypersensitivity—Sunitinib—kidney cancer	0.000323	0.000895	CcSEcCtD
Tapentadol—Decreased appetite—Vincristine—kidney cancer	0.000323	0.000893	CcSEcCtD
Tapentadol—Pruritus—Sorafenib—kidney cancer	0.000323	0.000893	CcSEcCtD
Tapentadol—Vomiting—Erlotinib—kidney cancer	0.000322	0.000892	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000321	0.000888	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Vincristine—kidney cancer	0.000321	0.000887	CcSEcCtD
Tapentadol—Fatigue—Vincristine—kidney cancer	0.00032	0.000886	CcSEcCtD
Tapentadol—Rash—Erlotinib—kidney cancer	0.00032	0.000884	CcSEcCtD
Tapentadol—Dermatitis—Erlotinib—kidney cancer	0.000319	0.000884	CcSEcCtD
Tapentadol—Palpitations—Paclitaxel—kidney cancer	0.000319	0.000883	CcSEcCtD
Tapentadol—Insomnia—Gemcitabine—kidney cancer	0.000319	0.000881	CcSEcCtD
Tapentadol—Eye disorder—Capecitabine—kidney cancer	0.000318	0.000881	CcSEcCtD
Tapentadol—Headache—Erlotinib—kidney cancer	0.000318	0.000879	CcSEcCtD
Tapentadol—Loss of consciousness—Paclitaxel—kidney cancer	0.000318	0.000879	CcSEcCtD
Tapentadol—Constipation—Vincristine—kidney cancer	0.000317	0.000878	CcSEcCtD
Tapentadol—Osteoarthritis—Doxorubicin—kidney cancer	0.000317	0.000878	CcSEcCtD
Tapentadol—Paraesthesia—Gemcitabine—kidney cancer	0.000316	0.000875	CcSEcCtD
Tapentadol—Cardiac disorder—Capecitabine—kidney cancer	0.000316	0.000875	CcSEcCtD
Tapentadol—Cough—Paclitaxel—kidney cancer	0.000315	0.000872	CcSEcCtD
Tapentadol—Asthenia—Sunitinib—kidney cancer	0.000315	0.000871	CcSEcCtD
Tapentadol—Dyspnoea—Gemcitabine—kidney cancer	0.000314	0.000869	CcSEcCtD
Tapentadol—Nausea—Vinblastine—kidney cancer	0.000313	0.000867	CcSEcCtD
Tapentadol—Somnolence—Gemcitabine—kidney cancer	0.000313	0.000866	CcSEcCtD
Tapentadol—Convulsion—Paclitaxel—kidney cancer	0.000313	0.000866	CcSEcCtD
Tapentadol—Nausea—Everolimus—kidney cancer	0.000312	0.000864	CcSEcCtD
Tapentadol—Diarrhoea—Sorafenib—kidney cancer	0.000312	0.000863	CcSEcCtD
Tapentadol—Pruritus—Sunitinib—kidney cancer	0.000311	0.000859	CcSEcCtD
Tapentadol—Angiopathy—Capecitabine—kidney cancer	0.000309	0.000855	CcSEcCtD
Tapentadol—Immune system disorder—Capecitabine—kidney cancer	0.000308	0.000851	CcSEcCtD
Tapentadol—Arthralgia—Paclitaxel—kidney cancer	0.000308	0.000851	CcSEcCtD
Tapentadol—Mediastinal disorder—Capecitabine—kidney cancer	0.000307	0.000849	CcSEcCtD
Tapentadol—Anxiety—Paclitaxel—kidney cancer	0.000307	0.000848	CcSEcCtD
Tapentadol—Decreased appetite—Gemcitabine—kidney cancer	0.000306	0.000847	CcSEcCtD
Tapentadol—Hypersensitivity—Dactinomycin—kidney cancer	0.000306	0.000847	CcSEcCtD
Tapentadol—Chills—Capecitabine—kidney cancer	0.000306	0.000846	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000305	0.000845	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000304	0.000841	CcSEcCtD
Tapentadol—Fatigue—Gemcitabine—kidney cancer	0.000304	0.00084	CcSEcCtD
Tapentadol—Dizziness—Sorafenib—kidney cancer	0.000302	0.000835	CcSEcCtD
Tapentadol—Constipation—Gemcitabine—kidney cancer	0.000301	0.000833	CcSEcCtD
Tapentadol—Nausea—Erlotinib—kidney cancer	0.000301	0.000833	CcSEcCtD
Tapentadol—Dry mouth—Paclitaxel—kidney cancer	0.000301	0.000832	CcSEcCtD
Tapentadol—Diarrhoea—Sunitinib—kidney cancer	0.0003	0.000831	CcSEcCtD
Tapentadol—Ataxia—Doxorubicin—kidney cancer	0.000298	0.000826	CcSEcCtD
Tapentadol—Mental disorder—Capecitabine—kidney cancer	0.000298	0.000826	CcSEcCtD
Tapentadol—Asthenia—Dactinomycin—kidney cancer	0.000298	0.000825	CcSEcCtD
Tapentadol—Confusional state—Paclitaxel—kidney cancer	0.000297	0.000823	CcSEcCtD
Tapentadol—Malnutrition—Capecitabine—kidney cancer	0.000297	0.00082	CcSEcCtD
Tapentadol—Anaphylactic shock—Paclitaxel—kidney cancer	0.000295	0.000816	CcSEcCtD
Tapentadol—Oedema—Paclitaxel—kidney cancer	0.000295	0.000816	CcSEcCtD
Tapentadol—Infection—Paclitaxel—kidney cancer	0.000293	0.00081	CcSEcCtD
Tapentadol—Dizziness—Sunitinib—kidney cancer	0.00029	0.000803	CcSEcCtD
Tapentadol—Feeling abnormal—Gemcitabine—kidney cancer	0.00029	0.000803	CcSEcCtD
Tapentadol—Shock—Paclitaxel—kidney cancer	0.00029	0.000803	CcSEcCtD
Tapentadol—Vomiting—Sorafenib—kidney cancer	0.00029	0.000802	CcSEcCtD
Tapentadol—Nervous system disorder—Paclitaxel—kidney cancer	0.000289	0.0008	CcSEcCtD
Tapentadol—Tachycardia—Paclitaxel—kidney cancer	0.000288	0.000796	CcSEcCtD
Tapentadol—Rash—Sorafenib—kidney cancer	0.000288	0.000796	CcSEcCtD
Tapentadol—Dermatitis—Sorafenib—kidney cancer	0.000287	0.000795	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—kidney cancer	0.000287	0.000793	CcSEcCtD
Tapentadol—Skin disorder—Paclitaxel—kidney cancer	0.000286	0.000792	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000286	0.000791	CcSEcCtD
Tapentadol—Headache—Sorafenib—kidney cancer	0.000286	0.000791	CcSEcCtD
Tapentadol—Hyperhidrosis—Paclitaxel—kidney cancer	0.000285	0.000789	CcSEcCtD
Tapentadol—Diarrhoea—Dactinomycin—kidney cancer	0.000284	0.000787	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—kidney cancer	0.000284	0.000785	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.00028	0.000774	CcSEcCtD
Tapentadol—Vision blurred—Capecitabine—kidney cancer	0.000279	0.000773	CcSEcCtD
Tapentadol—Vomiting—Sunitinib—kidney cancer	0.000279	0.000772	CcSEcCtD
Tapentadol—Tremor—Capecitabine—kidney cancer	0.000278	0.000769	CcSEcCtD
Tapentadol—Rash—Sunitinib—kidney cancer	0.000277	0.000766	CcSEcCtD
Tapentadol—Dermatitis—Sunitinib—kidney cancer	0.000276	0.000765	CcSEcCtD
Tapentadol—Hypotension—Paclitaxel—kidney cancer	0.000276	0.000762	CcSEcCtD
Tapentadol—Headache—Sunitinib—kidney cancer	0.000275	0.000761	CcSEcCtD
Tapentadol—Hypersensitivity—Vincristine—kidney cancer	0.000274	0.000757	CcSEcCtD
Tapentadol—Nausea—Sorafenib—kidney cancer	0.000271	0.00075	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000269	0.000743	CcSEcCtD
Tapentadol—Insomnia—Paclitaxel—kidney cancer	0.000267	0.000738	CcSEcCtD
Tapentadol—Vertigo—Capecitabine—kidney cancer	0.000266	0.000737	CcSEcCtD
Tapentadol—Asthenia—Vincristine—kidney cancer	0.000266	0.000737	CcSEcCtD
Tapentadol—Syncope—Capecitabine—kidney cancer	0.000266	0.000736	CcSEcCtD
Tapentadol—Paraesthesia—Paclitaxel—kidney cancer	0.000265	0.000733	CcSEcCtD
Tapentadol—Vomiting—Dactinomycin—kidney cancer	0.000264	0.000731	CcSEcCtD
Tapentadol—Dyspnoea—Paclitaxel—kidney cancer	0.000263	0.000727	CcSEcCtD
Tapentadol—Somnolence—Paclitaxel—kidney cancer	0.000262	0.000725	CcSEcCtD
Tapentadol—Palpitations—Capecitabine—kidney cancer	0.000262	0.000725	CcSEcCtD
Tapentadol—Rash—Dactinomycin—kidney cancer	0.000262	0.000725	CcSEcCtD
Tapentadol—Nausea—Sunitinib—kidney cancer	0.000261	0.000721	CcSEcCtD
Tapentadol—Loss of consciousness—Capecitabine—kidney cancer	0.000261	0.000721	CcSEcCtD
Tapentadol—Dyspepsia—Paclitaxel—kidney cancer	0.00026	0.000718	CcSEcCtD
Tapentadol—Cough—Capecitabine—kidney cancer	0.000259	0.000716	CcSEcCtD
Tapentadol—Decreased appetite—Paclitaxel—kidney cancer	0.000256	0.000709	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000255	0.000705	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000255	0.000704	CcSEcCtD
Tapentadol—Fatigue—Paclitaxel—kidney cancer	0.000254	0.000703	CcSEcCtD
Tapentadol—Diarrhoea—Vincristine—kidney cancer	0.000254	0.000703	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—kidney cancer	0.000253	0.000701	CcSEcCtD
Tapentadol—Asthenia—Gemcitabine—kidney cancer	0.000253	0.000699	CcSEcCtD
Tapentadol—Arthralgia—Capecitabine—kidney cancer	0.000252	0.000698	CcSEcCtD
Tapentadol—Constipation—Paclitaxel—kidney cancer	0.000252	0.000698	CcSEcCtD
Tapentadol—Anxiety—Capecitabine—kidney cancer	0.000252	0.000696	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000251	0.000694	CcSEcCtD
Tapentadol—Pruritus—Gemcitabine—kidney cancer	0.000249	0.000689	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—kidney cancer	0.000248	0.000687	CcSEcCtD
Tapentadol—Dry mouth—Capecitabine—kidney cancer	0.000247	0.000683	CcSEcCtD
Tapentadol—Nausea—Dactinomycin—kidney cancer	0.000247	0.000683	CcSEcCtD
Tapentadol—Dizziness—Vincristine—kidney cancer	0.000246	0.000679	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—kidney cancer	0.000245	0.000677	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—kidney cancer	0.000245	0.000677	CcSEcCtD
Tapentadol—Confusional state—Capecitabine—kidney cancer	0.000244	0.000675	CcSEcCtD
Tapentadol—Feeling abnormal—Paclitaxel—kidney cancer	0.000243	0.000672	CcSEcCtD
Tapentadol—Oedema—Capecitabine—kidney cancer	0.000242	0.000669	CcSEcCtD
Tapentadol—Diarrhoea—Gemcitabine—kidney cancer	0.000241	0.000667	CcSEcCtD
Tapentadol—Infection—Capecitabine—kidney cancer	0.00024	0.000665	CcSEcCtD
Tapentadol—Shock—Capecitabine—kidney cancer	0.000238	0.000659	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—kidney cancer	0.000238	0.000658	CcSEcCtD
Tapentadol—Nervous system disorder—Capecitabine—kidney cancer	0.000237	0.000657	CcSEcCtD
Tapentadol—Tachycardia—Capecitabine—kidney cancer	0.000236	0.000653	CcSEcCtD
Tapentadol—Vomiting—Vincristine—kidney cancer	0.000236	0.000653	CcSEcCtD
Tapentadol—Skin disorder—Capecitabine—kidney cancer	0.000235	0.00065	CcSEcCtD
Tapentadol—Urticaria—Paclitaxel—kidney cancer	0.000234	0.000648	CcSEcCtD
Tapentadol—Rash—Vincristine—kidney cancer	0.000234	0.000648	CcSEcCtD
Tapentadol—Hyperhidrosis—Capecitabine—kidney cancer	0.000234	0.000647	CcSEcCtD
Tapentadol—Dermatitis—Vincristine—kidney cancer	0.000234	0.000647	CcSEcCtD
Tapentadol—Headache—Vincristine—kidney cancer	0.000233	0.000643	CcSEcCtD
Tapentadol—Hypotension—Capecitabine—kidney cancer	0.000226	0.000626	CcSEcCtD
Tapentadol—Vomiting—Gemcitabine—kidney cancer	0.000224	0.00062	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—kidney cancer	0.000224	0.000618	CcSEcCtD
Tapentadol—Rash—Gemcitabine—kidney cancer	0.000222	0.000614	CcSEcCtD
Tapentadol—Dermatitis—Gemcitabine—kidney cancer	0.000222	0.000614	CcSEcCtD
Tapentadol—Headache—Gemcitabine—kidney cancer	0.000221	0.00061	CcSEcCtD
Tapentadol—Nausea—Vincristine—kidney cancer	0.000221	0.00061	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.00022	0.00061	CcSEcCtD
Tapentadol—Insomnia—Capecitabine—kidney cancer	0.000219	0.000606	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—kidney cancer	0.000218	0.000604	CcSEcCtD
Tapentadol—Paraesthesia—Capecitabine—kidney cancer	0.000217	0.000601	CcSEcCtD
Tapentadol—Hypersensitivity—Paclitaxel—kidney cancer	0.000217	0.000601	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—kidney cancer	0.000217	0.0006	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—kidney cancer	0.000216	0.000597	CcSEcCtD
Tapentadol—Dyspnoea—Capecitabine—kidney cancer	0.000216	0.000597	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—kidney cancer	0.000215	0.000595	CcSEcCtD
Tapentadol—Dyspepsia—Capecitabine—kidney cancer	0.000213	0.000589	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—kidney cancer	0.000212	0.000585	CcSEcCtD
Tapentadol—Asthenia—Paclitaxel—kidney cancer	0.000212	0.000585	CcSEcCtD
Tapentadol—Decreased appetite—Capecitabine—kidney cancer	0.00021	0.000582	CcSEcCtD
Tapentadol—Nausea—Gemcitabine—kidney cancer	0.000209	0.000579	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000209	0.000578	CcSEcCtD
Tapentadol—Fatigue—Capecitabine—kidney cancer	0.000209	0.000577	CcSEcCtD
Tapentadol—Pruritus—Paclitaxel—kidney cancer	0.000209	0.000577	CcSEcCtD
Tapentadol—Constipation—Capecitabine—kidney cancer	0.000207	0.000572	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—kidney cancer	0.000205	0.000568	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—kidney cancer	0.000204	0.000564	CcSEcCtD
Tapentadol—Diarrhoea—Paclitaxel—kidney cancer	0.000202	0.000558	CcSEcCtD
Tapentadol—Feeling abnormal—Capecitabine—kidney cancer	0.000199	0.000552	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—kidney cancer	0.000199	0.000551	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—kidney cancer	0.000198	0.000549	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—kidney cancer	0.000198	0.000547	CcSEcCtD
Tapentadol—Chills—Doxorubicin—kidney cancer	0.000197	0.000545	CcSEcCtD
Tapentadol—Dizziness—Paclitaxel—kidney cancer	0.000195	0.000539	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—kidney cancer	0.000192	0.000532	CcSEcCtD
Tapentadol—Urticaria—Capecitabine—kidney cancer	0.000192	0.000532	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—kidney cancer	0.000191	0.000529	CcSEcCtD
Tapentadol—Tension—Doxorubicin—kidney cancer	0.000188	0.000519	CcSEcCtD
Tapentadol—Vomiting—Paclitaxel—kidney cancer	0.000187	0.000519	CcSEcCtD
Tapentadol—Rash—Paclitaxel—kidney cancer	0.000186	0.000514	CcSEcCtD
Tapentadol—Dermatitis—Paclitaxel—kidney cancer	0.000186	0.000514	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—kidney cancer	0.000186	0.000514	CcSEcCtD
Tapentadol—Headache—Paclitaxel—kidney cancer	0.000185	0.000511	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—kidney cancer	0.00018	0.000498	CcSEcCtD
Tapentadol—Hypersensitivity—Capecitabine—kidney cancer	0.000178	0.000493	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—kidney cancer	0.000176	0.000486	CcSEcCtD
Tapentadol—Nausea—Paclitaxel—kidney cancer	0.000175	0.000485	CcSEcCtD
Tapentadol—Asthenia—Capecitabine—kidney cancer	0.000174	0.00048	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—kidney cancer	0.000172	0.000475	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—kidney cancer	0.000171	0.000474	CcSEcCtD
Tapentadol—Pruritus—Capecitabine—kidney cancer	0.000171	0.000474	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—kidney cancer	0.000169	0.000467	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—kidney cancer	0.000168	0.000465	CcSEcCtD
Tapentadol—Cough—Doxorubicin—kidney cancer	0.000167	0.000461	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—kidney cancer	0.000166	0.000458	CcSEcCtD
Tapentadol—Diarrhoea—Capecitabine—kidney cancer	0.000166	0.000458	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—kidney cancer	0.000163	0.00045	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—kidney cancer	0.000162	0.000449	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000162	0.000447	CcSEcCtD
Tapentadol—Dizziness—Capecitabine—kidney cancer	0.00016	0.000443	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—kidney cancer	0.000159	0.00044	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—kidney cancer	0.000157	0.000435	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—kidney cancer	0.000156	0.000432	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—kidney cancer	0.000156	0.000432	CcSEcCtD
Tapentadol—Infection—Doxorubicin—kidney cancer	0.000155	0.000429	CcSEcCtD
Tapentadol—Vomiting—Capecitabine—kidney cancer	0.000154	0.000426	CcSEcCtD
Tapentadol—Shock—Doxorubicin—kidney cancer	0.000153	0.000425	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—kidney cancer	0.000153	0.000423	CcSEcCtD
Tapentadol—Rash—Capecitabine—kidney cancer	0.000153	0.000422	CcSEcCtD
Tapentadol—Dermatitis—Capecitabine—kidney cancer	0.000152	0.000422	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—kidney cancer	0.000152	0.000421	CcSEcCtD
Tapentadol—Headache—Capecitabine—kidney cancer	0.000152	0.000419	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—kidney cancer	0.000152	0.000419	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—kidney cancer	0.000151	0.000417	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—kidney cancer	0.000146	0.000403	CcSEcCtD
Tapentadol—Nausea—Capecitabine—kidney cancer	0.000144	0.000398	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000142	0.000393	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—kidney cancer	0.000141	0.00039	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—kidney cancer	0.00014	0.000388	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—kidney cancer	0.000139	0.000385	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—kidney cancer	0.000139	0.000384	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—kidney cancer	0.000137	0.00038	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—kidney cancer	0.000136	0.000375	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000135	0.000373	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—kidney cancer	0.000134	0.000372	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—kidney cancer	0.000133	0.000369	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—kidney cancer	0.000129	0.000356	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—kidney cancer	0.000124	0.000343	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—kidney cancer	0.000115	0.000318	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—kidney cancer	0.000112	0.00031	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—kidney cancer	0.00011	0.000305	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—kidney cancer	0.000107	0.000295	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—kidney cancer	0.000103	0.000285	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—kidney cancer	9.92e-05	0.000274	CcSEcCtD
Tapentadol—Rash—Doxorubicin—kidney cancer	9.84e-05	0.000272	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—kidney cancer	9.83e-05	0.000272	CcSEcCtD
Tapentadol—Headache—Doxorubicin—kidney cancer	9.77e-05	0.00027	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—kidney cancer	9.27e-05	0.000256	CcSEcCtD
Tapentadol—UGT1A9—Metabolism—PSMD7—kidney cancer	3.13e-05	0.000423	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	3.1e-05	0.000419	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUNB—kidney cancer	3.1e-05	0.000419	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PAK1—kidney cancer	3.1e-05	0.000419	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	3.07e-05	0.000415	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ITPR2—kidney cancer	3.05e-05	0.000412	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PSMD7—kidney cancer	3.03e-05	0.000409	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TSC1—kidney cancer	3.03e-05	0.000409	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ANXA1—kidney cancer	3.03e-05	0.000409	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPC3—kidney cancer	3.01e-05	0.000407	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—BCHE—kidney cancer	2.96e-05	0.000401	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APRT—kidney cancer	2.94e-05	0.000398	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—FH—kidney cancer	2.94e-05	0.000398	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FLT1—kidney cancer	2.93e-05	0.000396	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SLC5A5—kidney cancer	2.93e-05	0.000396	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CA2—kidney cancer	2.93e-05	0.000396	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—FH—kidney cancer	2.92e-05	0.000395	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APRT—kidney cancer	2.92e-05	0.000395	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTP1—kidney cancer	2.9e-05	0.000392	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—POMC—kidney cancer	2.86e-05	0.000387	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALAD—kidney cancer	2.85e-05	0.000386	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.85e-05	0.000386	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SLC2A1—kidney cancer	2.83e-05	0.000382	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—RAF1—kidney cancer	2.81e-05	0.00038	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ST3GAL2—kidney cancer	2.79e-05	0.000376	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPC3—kidney cancer	2.77e-05	0.000374	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNA1—kidney cancer	2.77e-05	0.000374	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—POMC—kidney cancer	2.76e-05	0.000374	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EIF4EBP1—kidney cancer	2.75e-05	0.000372	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HSPB1—kidney cancer	2.75e-05	0.000372	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ABCB1—kidney cancer	2.75e-05	0.000371	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPC3—kidney cancer	2.74e-05	0.000371	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.74e-05	0.000371	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALDH1A1—kidney cancer	2.72e-05	0.000368	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUNB—kidney cancer	2.72e-05	0.000367	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PAK1—kidney cancer	2.72e-05	0.000367	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CA2—kidney cancer	2.69e-05	0.000364	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CA2—kidney cancer	2.67e-05	0.000361	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTM1—kidney cancer	2.67e-05	0.000361	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALAD—kidney cancer	2.62e-05	0.000355	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PGK1—kidney cancer	2.61e-05	0.000353	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC5A3—kidney cancer	2.61e-05	0.000353	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALAD—kidney cancer	2.6e-05	0.000352	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ST3GAL2—kidney cancer	2.56e-05	0.000346	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LDHB—kidney cancer	2.56e-05	0.000346	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PSMD7—kidney cancer	2.56e-05	0.000346	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TSC1—kidney cancer	2.56e-05	0.000346	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ANXA1—kidney cancer	2.56e-05	0.000346	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ST3GAL2—kidney cancer	2.54e-05	0.000343	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF2—kidney cancer	2.53e-05	0.000342	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP1A1—kidney cancer	2.53e-05	0.000342	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN2B—kidney cancer	2.52e-05	0.000341	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—POMC—kidney cancer	2.51e-05	0.000339	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALDH1A1—kidney cancer	2.5e-05	0.000338	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALDH1A1—kidney cancer	2.48e-05	0.000336	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FLT1—kidney cancer	2.48e-05	0.000335	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1R—kidney cancer	2.45e-05	0.000331	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC5A3—kidney cancer	2.4e-05	0.000324	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PGK1—kidney cancer	2.4e-05	0.000324	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.39e-05	0.000323	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PGK1—kidney cancer	2.38e-05	0.000322	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC5A3—kidney cancer	2.38e-05	0.000322	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—RAF1—kidney cancer	2.36e-05	0.000319	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTP1—kidney cancer	2.36e-05	0.000319	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LDHB—kidney cancer	2.35e-05	0.000318	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—POMC—kidney cancer	2.34e-05	0.000316	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LDHB—kidney cancer	2.33e-05	0.000315	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—IL2—kidney cancer	2.33e-05	0.000315	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUNB—kidney cancer	2.3e-05	0.00031	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PAK1—kidney cancer	2.3e-05	0.00031	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ABCB1—kidney cancer	2.23e-05	0.000302	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF2—kidney cancer	2.22e-05	0.0003	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CA9—kidney cancer	2.22e-05	0.0003	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN2B—kidney cancer	2.21e-05	0.000299	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.17e-05	0.000293	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTM1—kidney cancer	2.17e-05	0.000293	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1R—kidney cancer	2.15e-05	0.00029	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—POMC—kidney cancer	2.12e-05	0.000287	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL2—kidney cancer	2.12e-05	0.000286	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—RAF1—kidney cancer	2.07e-05	0.00028	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP1A1—kidney cancer	2.06e-05	0.000278	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—IL2—kidney cancer	2.04e-05	0.000276	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CA9—kidney cancer	2.04e-05	0.000276	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CA9—kidney cancer	2.02e-05	0.000273	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HIF1A—kidney cancer	2.02e-05	0.000272	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TSC2—kidney cancer	2.01e-05	0.000272	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.98e-05	0.000267	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KDR—kidney cancer	1.93e-05	0.000261	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CRABP1—kidney cancer	1.89e-05	0.000255	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—POMC—kidney cancer	1.89e-05	0.000255	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF2—kidney cancer	1.88e-05	0.000254	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN2B—kidney cancer	1.87e-05	0.000253	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL2—kidney cancer	1.86e-05	0.000251	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1R—kidney cancer	1.81e-05	0.000245	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KIT—kidney cancer	1.78e-05	0.00024	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APC—kidney cancer	1.78e-05	0.00024	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HIF1A—kidney cancer	1.77e-05	0.000239	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TSC2—kidney cancer	1.76e-05	0.000238	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ITPR2—kidney cancer	1.75e-05	0.000237	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—RAF1—kidney cancer	1.75e-05	0.000236	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CRABP1—kidney cancer	1.74e-05	0.000235	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL2—kidney cancer	1.73e-05	0.000233	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CRABP1—kidney cancer	1.72e-05	0.000233	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK3—kidney cancer	1.7e-05	0.00023	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—POMC—kidney cancer	1.69e-05	0.000229	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KDR—kidney cancer	1.69e-05	0.000229	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.69e-05	0.000228	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—BRAF—kidney cancer	1.67e-05	0.000226	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK1—kidney cancer	1.62e-05	0.000219	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.62e-05	0.000219	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ITPR2—kidney cancer	1.61e-05	0.000218	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTT1—kidney cancer	1.6e-05	0.000216	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ACHE—kidney cancer	1.6e-05	0.000216	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ITPR2—kidney cancer	1.6e-05	0.000216	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—kidney cancer	1.57e-05	0.000212	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KIT—kidney cancer	1.56e-05	0.000211	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APC—kidney cancer	1.56e-05	0.000211	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—kidney cancer	1.55e-05	0.000209	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—POMC—kidney cancer	1.53e-05	0.000207	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—kidney cancer	1.53e-05	0.000207	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SCARB1—kidney cancer	1.51e-05	0.000205	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—kidney cancer	1.5e-05	0.000203	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS1—kidney cancer	1.5e-05	0.000203	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HIF1A—kidney cancer	1.49e-05	0.000202	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK3—kidney cancer	1.49e-05	0.000202	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TSC2—kidney cancer	1.49e-05	0.000201	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—POMC—kidney cancer	1.48e-05	0.0002	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.47e-05	0.000199	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTT1—kidney cancer	1.47e-05	0.000199	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ACHE—kidney cancer	1.47e-05	0.000199	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSMD7—kidney cancer	1.47e-05	0.000199	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BRAF—kidney cancer	1.46e-05	0.000198	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTT1—kidney cancer	1.46e-05	0.000197	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ACHE—kidney cancer	1.46e-05	0.000197	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KDR—kidney cancer	1.43e-05	0.000193	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK1—kidney cancer	1.42e-05	0.000192	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—kidney cancer	1.4e-05	0.00019	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RAF1—kidney cancer	1.39e-05	0.000188	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—BCHE—kidney cancer	1.39e-05	0.000188	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SCARB1—kidney cancer	1.39e-05	0.000188	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RELA—kidney cancer	1.39e-05	0.000188	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SCARB1—kidney cancer	1.38e-05	0.000187	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—kidney cancer	1.38e-05	0.000186	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS1—kidney cancer	1.38e-05	0.000186	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC5A5—kidney cancer	1.38e-05	0.000186	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS1—kidney cancer	1.37e-05	0.000185	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MTOR—kidney cancer	1.36e-05	0.000184	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—kidney cancer	1.36e-05	0.000183	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSMD7—kidney cancer	1.35e-05	0.000183	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—kidney cancer	1.34e-05	0.000181	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSMD7—kidney cancer	1.34e-05	0.000181	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A1—kidney cancer	1.33e-05	0.00018	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APC—kidney cancer	1.32e-05	0.000178	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KIT—kidney cancer	1.32e-05	0.000178	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—kidney cancer	1.31e-05	0.000177	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.29e-05	0.000174	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—BCHE—kidney cancer	1.28e-05	0.000173	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1B—kidney cancer	1.28e-05	0.000173	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—BCHE—kidney cancer	1.27e-05	0.000172	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.27e-05	0.000171	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—kidney cancer	1.26e-05	0.00017	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC5A5—kidney cancer	1.26e-05	0.00017	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—POMC—kidney cancer	1.25e-05	0.000169	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—kidney cancer	1.25e-05	0.000169	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—kidney cancer	1.24e-05	0.000167	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—kidney cancer	1.23e-05	0.000166	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.22e-05	0.000165	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAF1—kidney cancer	1.22e-05	0.000165	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—kidney cancer	1.22e-05	0.000165	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—kidney cancer	1.22e-05	0.000165	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RELA—kidney cancer	1.22e-05	0.000164	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—kidney cancer	1.22e-05	0.000164	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A1—kidney cancer	1.21e-05	0.000164	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—kidney cancer	1.21e-05	0.000163	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CTNNB1—kidney cancer	1.21e-05	0.000163	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK1—kidney cancer	1.2e-05	0.000162	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MTOR—kidney cancer	1.19e-05	0.000161	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.18e-05	0.000159	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—kidney cancer	1.18e-05	0.000159	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—kidney cancer	1.15e-05	0.000155	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—kidney cancer	1.13e-05	0.000153	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.12e-05	0.000152	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1B—kidney cancer	1.12e-05	0.000151	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—kidney cancer	1.11e-05	0.00015	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—kidney cancer	1.1e-05	0.000148	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—kidney cancer	1.07e-05	0.000144	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—kidney cancer	1.07e-05	0.000144	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—kidney cancer	1.07e-05	0.000144	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—kidney cancer	1.06e-05	0.000144	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CTNNB1—kidney cancer	1.06e-05	0.000143	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—kidney cancer	1.05e-05	0.000142	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—kidney cancer	1.04e-05	0.000141	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAF1—kidney cancer	1.03e-05	0.00014	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—kidney cancer	1.03e-05	0.000139	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RELA—kidney cancer	1.03e-05	0.000139	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.03e-05	0.000139	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—kidney cancer	1.02e-05	0.000138	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—kidney cancer	1.02e-05	0.000138	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—kidney cancer	1.02e-05	0.000138	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—kidney cancer	1.01e-05	0.000137	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MTOR—kidney cancer	1.01e-05	0.000136	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—kidney cancer	1e-05	0.000136	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—kidney cancer	9.77e-06	0.000132	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A1—kidney cancer	9.66e-06	0.000131	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—kidney cancer	9.65e-06	0.00013	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—kidney cancer	9.57e-06	0.000129	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK1—kidney cancer	9.56e-06	0.000129	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1B—kidney cancer	9.47e-06	0.000128	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—kidney cancer	9.37e-06	0.000127	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—kidney cancer	9.31e-06	0.000126	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—kidney cancer	9.29e-06	0.000126	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—kidney cancer	9.26e-06	0.000125	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—kidney cancer	9.25e-06	0.000125	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—kidney cancer	9.03e-06	0.000122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—kidney cancer	9.03e-06	0.000122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—kidney cancer	9.01e-06	0.000122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNB1—kidney cancer	8.94e-06	0.000121	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A1—kidney cancer	8.88e-06	0.00012	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—kidney cancer	8.81e-06	0.000119	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A1—kidney cancer	8.81e-06	0.000119	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—kidney cancer	8.72e-06	0.000118	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—kidney cancer	8.57e-06	0.000116	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK1—kidney cancer	8.38e-06	0.000113	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—kidney cancer	8.3e-06	0.000112	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—kidney cancer	8.03e-06	0.000108	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.94e-06	0.000107	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—kidney cancer	7.92e-06	0.000107	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—kidney cancer	7.87e-06	0.000106	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—kidney cancer	7.52e-06	0.000102	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—kidney cancer	7.45e-06	0.000101	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—kidney cancer	7.27e-06	9.83e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—kidney cancer	7.24e-06	9.79e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.24e-06	9.78e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—POMC—kidney cancer	7.2e-06	9.73e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK1—kidney cancer	7.09e-06	9.58e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—kidney cancer	7.04e-06	9.51e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—kidney cancer	6.69e-06	9.05e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—POMC—kidney cancer	6.62e-06	8.95e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—POMC—kidney cancer	6.57e-06	8.88e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—kidney cancer	6.15e-06	8.31e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—kidney cancer	5.95e-06	8.04e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—kidney cancer	5.74e-06	7.76e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—kidney cancer	5.28e-06	7.14e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—kidney cancer	5.24e-06	7.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—kidney cancer	5.01e-06	6.77e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—kidney cancer	4.61e-06	6.23e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—kidney cancer	4.57e-06	6.17e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—kidney cancer	3.53e-06	4.78e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—kidney cancer	3.25e-06	4.39e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—kidney cancer	3.22e-06	4.36e-05	CbGpPWpGaD
